modelJ07AG54
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | HaemophilusInfluenzaBCombinationsWithMeningococcusCYConjugated | |
| ATC code: | J07AG54 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 0.5 | mg |
| volume of distribution: | 3 | L |
| clearance: | 0.1 | L/hour |
| other parameters in model implementation | ||
A combination vaccine containing purified polysaccharides from Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroups C and Y, each conjugated to a carrier protein (commonly tetanus toxoid or CRM197). This vaccine is used for the active immunization of infants and young children against invasive diseases caused by Hib and meningococcal serogroups C and Y. Such vaccines are approved in various countries and included in immunization schedules for pediatric population.
Pharmacokinetics
No published pharmacokinetic studies specifically reporting plasma or tissue concentration PK parameters for Hib-MenCY conjugated vaccines were found. Vaccines are administered intramuscularly and their pharmacokinetics is typically described in terms of immunogenicity (antibody titers) rather than typical small molecule PK parameters. Parameters provided below are estimated based on general characteristics of conjugate vaccines administered intramuscularly in infants/children.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)